The Bio Report

The Bio Report episodes:

• 04.24.2024

  A New Class of Cell Therapies to Target Solid Tumors

  Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of...

  
• 04.17.2024

  Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

  Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

  
• 04.10.2024

  A Company Born from a Father Who Wore His Heart on His Sleeve

  Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.

  
• 04.03.2024

  Using AI to Improve Burn Care

  Pete Carlson, CEO of Spectral AI, discusses the company’s AI-driven DeepView System for assessing burns, how it provides clinicians an objective and immediate assessment of a wound’s healing potential, and how it changes outcomes for patients.

  
• 03.27.2024

  A Home for Biotech in the City that Never Sleeps

  New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number...

  
• 03.20.2024

  Biopharma R&D Growing Stronger

  Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 billion...

  
• 03.13.2024

  The Benefits of Having a Multitude of Cins

  Jon Isaacsohn, founder and CEO of CinRx, discusses the company’s portfolio approach, how its business model allows it to accelerate the development of needed medicines, and its efforts to develop new obesity therapies.

  
• 03.06.2024

  Making ADCs Smarter and Safer with a Simple Twist of Fate

  Brian Fiske, co-founder, chief scientific officer of Mythic Therapeutics, discusses the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.

  
• 02.28.2024

  Targeting a Natural Repair System to Restore Brain Health

  Rachel Lenington, chief operating officer of Athira Pharma, discusses the case for targeting the HGF/MET neurotrophic system in neurodegenerative diseases, how its experimental therapy fosgonimeton works, and why its continuing to pursue the therapy despite earlier failures.

  
• 02.21.2024

  Programing Cells in a Predictable and Scalable Way

  Mark Kotter, founder and CEO of Bit.Bio, discusses the company’s platform technology, its effort to develop cell therapies, and its growing offering of precision reprogramed human cells for drug development.

  
• 02.14.2024

  Why DNA May Be the Data Storage Medium of the Future

  Erfane Awani, founder and CEO of Biomemory, discusses the use of DNA for data storage, how it works, and how quickly the technology can scale to where it competes with today’s data storage infrastructure.

  
• 02.07.2024

  Scouring Genetic Variation within Our Cells for Drug Targets

  Jacob Rubens, president of Quotient Therapeutics, discusses the company’s platform technology, how it uncovers genetic mutations at a cellular level, and its efforts to build a pipeline of therapies around the insights it gains.

  
• 01.31.2024

  Correcting Gene Dysregulation to Treat Diseases

  Mahesh Karande, president and CEO of Omega Therapeutics, discusses his company’s pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.

  
• 01.24.2024

  Using Technology to Regain Abilities after Spinal Cord Injury

  Larry Jasinski, CEO of ReWalk Robotics, discusses the company’s Personal Exoskeleton, how it works, and the impact it can have on the quality of life for someone with a spinal cord injury.

  
• 01.17.2024

  Why Drug Developers Have a Growing Interest in Targeting Mitochondria

  Navdeep Chandel, professor of medicine in the Division of Pulmonary and Critical Care and of biochemistry and molecular genetics at the Feinberg School of Medicine, about the state of our understanding of mitochondria, why drug developers are pursuing therapies to...

  
• 01.10.2024

  Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates

  Nadia Harhen, general manager of simulation and optimization for SandboxAQ, discusses the challenges of drug development it is seeking to address, how Sandbox AQ is leveraging quantum technologies, and why it is seeking to tackle an intractable set of diseases.

  
• 01.03.2024

  Targeting a Multitude of CIN in Cancer Cells

  Charles Hugh-Jones, CEO of Volastra, discusses chromosomal instability in cancer cells, how the company is developing a pipeline of therapies to exploit this, and its expanding relationships with Big Pharma .

  
• 12.27.2023

  The Year in Biotech and What’s Ahead in 2024

  Adam Feuerstein, Polk award-winning journalist and senior biotech writer for STAT. discusses the biotech news that shaped 2023, the year’s best and worst CEOs, and what’s ahead in 2024.

  
• 12.20.2023

  Transforming Healthcare with Data

  Vik Bajaj, founder and CEO of Foresite Labs, discusses the changing data landscape around healthcare, the potential for technology to improve health outcomes, and what it takes for an entrepreneur to get his attention today.

  
• 12.13.2023

  Realizing the Promise of IL-2 Therapies with AI

  Aron Knickerbocker, president and CEO of Aulos Bioscience, discusses the potential for IL-2 therapies to treat solid tumors, the limits of today’s IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.

  
• 12.06.2023

  Unlocking Real-World Data to Improve Outcomes

  Sujay Jadhav, CEO of Verana Health, discusses the potential for real-world data to improve outcomes for patients, how Verana is addressing challenges these data can present, and the areas of medicine on which it is focused.

  
• 11.29.2023

  A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech

  Swaroop “Kittu” Kolluri, founder and managing director Neotribe Ventures, discusses the state of AI, the ability of technology to transform the healthcare environment, and Neotribe’s approach to investing.

  
• 11.22.2023

  A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

  Tom Miller, co-founder and CEO of Iambic Therapeutics, discusses the company’s AI platform, the insights Iambic gains from using a quantum mechanics-based approach to drug discovery, and its growing pipeline of cancer therapies.

  
• 11.15.2023

  Detecting Alzheimer’s Disease Early through a Blood Test

  John McDonough, executive chair and CEO of Sunbird Bio, discusses the company’s diagnostic test in development for Alzheimer’s disease, how it has the potential to impact treatments and outcomes for millions of patients with the condition, and how its merger...

  
• 11.08.2023

  Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology

  Christina Smolke, co-founder and CEO of Antheia, about the supply-chain challenges underlying drug shortages, how the company is using synthetic biology to create a reliable supply of active pharmaceutical ingredients, and its growing pipeline of products in development.

  
• 11.01.2023

  Building Better and More Affordable Vaccines

  Thomas Rademacher, co-founder and CEO of Emergex Vaccines, discusses the company’s platform technologies, the manufacturing advantages they offer, and its pursuit of universal coronavirus and influenza vaccines that work across variants.

  
• 10.25.2023

  Overcoming Resistance to Targeted Therapies

  Stacy Blain, co-founder and chief scientific officer of Concarlo, discusses the development of drug resistance in cancer, the company’s initial focus on breast cancer, and her own journey from academia to biopharma.

  
• 10.18.2023

  Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies

  Howard Davis, CEO of Akamis Bio, discusses the challenges immunotherapies have faced in addressing solid tumors, the company’s tumor gene therapy platform, and how it turns tumors against themselves to stimulate an immune response.

  
• 10.11.2023

  Using AI to Generate Mini-Protein Therapeutics

  David Longo, co-founder and CEO of Ordaōs, discusses the company’s focus on mini-proteins, its generative AI platform, and why its building its own pipeline around rare disease indications and partnering with other drug developers on other indications.

  
• 10.04.2023

  Inhibiting Cell Death to Preserve Vision in Retinal Diseases

  Connie Chang, chief operating officer for ONL Therapeutics, discusses the role Fas-signaling plays in cell death, how this underlies a number of retinal diseases, and the company’s experimental therapy to inhibit Fas signaling to treat these conditions.

  
• 09.27.2023

  Leveraging Generative AI to Design Therapeutic Antibodies

  James Field, founder and CEO of LabGenius, discusses the company’s use of generative AI to discover new therapeutic antibodies, its initial focus on immunotherapies, why he thinks the data the company is generating to train its AI system is a...

  
• 09.20.2023

  Managing Pain without Addiction

  Ketan Mehta, founder and CEO of Tris Pharma, discusses its experimental opiod Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis.

  
• 09.13.2023

  Using AI to Match Cancer Patients to their Best Treatment Options

  Tzvia Bader, co-founder and CEO of Leal Health, discusses her own experience with cancer, how that led to the creation of Leal Health, and how it is harnessing AI to connect patients to clinical trials based on their exact diagnoses.

  
• 09.06.2023

  A Venture Capitalist’s View of the Current Biotech Landscape

  Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.

  
• 08.30.2023

  Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent

  Bonum Therapeutics Chief Scientific Officer Diane Hollenbaugh and Bonum Chief Business Officer Neela Patel discuss the therapeutic potential of cytokines, the challenges of using them as therapeutics, and why Bonum’s context-dependent cytokines may enable wider use of these proteins to...

  
• 08.23.2023

  Targeting Cancer and Autoimmune Conditions with Donor-Derived EBV T Cells

  Pascal Touchon, president and CEO of Atara Biotherapeutics, discusses the role of the Epstein-Barr virus in certain cancers and autoimmune conditions, the company’s platform technology for allogenic CAR T therapies, and why it has implications beyond EBV-driven diseases.

  
• 08.16.2023

  Reprogramming the Tumor Microenviroment to Activate an Immune Response

  Randy Schatzman, CEO of Bolt Biotherapeutics, discusses the company’s immune-stimulating antibody conjugates, the case for activating both the innate and adaptive immune systems to fight cancer, and the company’s lead experimental therapy for HER2 positive cancers.

  
• 08.09.2023

  Making Safer and More Effective Vaccines with Targeted mRNA

  Thomas VanCott, chief scientific officer of Combined Therapeutics, discusses the company’s mRNA platform for vaccines, the advantages it provides, and its potential to use the same approach to train the immune system on specific mutations in a tumor.

  
• 08.02.2023

  Addressing a Global Need with RNA Vaccines and Immunotherapies

  Chris Pirie, co-founder and chief operating officer of HDT Bio, discusses the problem antibiotic resistance in developing nations, its platform technology for producing safe and stable RNA vaccines, and the potential to use the same platform to produce immunotherapies for...

  
• 07.26.2023

  Targeting Bacteria in Chronic Diseases

  Jonathan Solomon, CEO of BiomX, discusses the case for phage therapies, the company’s approach to creating a phage cocktail that could effectively target a population of patients, and why it’s focusing on chronic diseases.

  
• 07.19.2023

  Targeting Solid Tumors with Off-The-Shelf CAR T Therapies

  Wee Kiat Tan, chief operating officer of CytoMed, discusses the company’s platform technology for off-the-shelf CAR T therapies, the advantages they provide over existing autologous CAR T therapies, and why he believes they will be successful at treating solid tumors.

  
• 07.12.2023

  Reimagining the Development of Immunotherapies with a Venture Studio

  Max Krummel, founder and managing member of Foundery Innovations, discusses the venture studio’s business model, the resources it brings to bear, and how it works with academic researchers and universities.

  
• 07.05.2023

  Repairing the Body with Advanced Cell Therapies

  Nick Colangelo, president and CEO of Vericel, discusses the sports medicine and burn care markets the company is targeting, how its products are changing outcomes for patients, and the company’s plans for growth.

  
• 06.28.2023

  Achieving Precision with AI Pathology

  Ken Bloom, head of pathology for Nucleai, discusses the company’s AI spatial biology platform, how it works, and the potential it has to advance precision medicine.

  
• 06.21.2023

  Inducing Potent and Durable T Cell Responses to Fight Disease

  Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.

  
• 06.14.2023

  Developing Immunotherapies that Target the Drivers of Cancer

  Jak Knowles, CEO of Affini-T Therapeutics, discusses the company’s TCR-T cell therapies that target the drivers of a cancer, how they are engineered, and why they have the potential to be effective at treating solid tumors that have evaded the...

  
• 06.07.2023

  Using Phase 0 Trials to Bring Precision Medicine to Treating Brain Tumors

  Nader Sanai, director of the Ivy Brain Tumor Center and chief of neurosurgical oncology at the Barrow Neurological Institute, discusses phase 0 clinical trials, how they work, and how they are allowing the center to take a precision medicine approach...

  
• 05.31.2023

  Restoring Feeling and Function to Damaged Nerves

  Karen Zaderej, CEO of Axogen, discusses peripheral nerve injuries, the company’s portfolio of products, and how it is changing the way surgeons can repair and regenerate damaged nerves.

  
• 05.24.2023

  Enlisting Vaccines in the Fight Against Chronic Diseases

  Mei Mei Hu, CEO of Vaxxinity, discusses the case for using vaccines to address chronic diseases, the benefits this approach provides, and how its platform technology activates the immune system to battle non-communicable diseases.

  
• 05.17.2023

  Extending the Reach of Protein Degradation Therapies

  Rami Hannoush co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and how its built an atlas of tissue-specific degrader antibodies to target proteins involved in...